Sagimet Biosciences Past Earnings Performance
Past criteria checks 0/6
Sagimet Biosciences's earnings have been declining at an average annual rate of -18.4%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 97.1% per year.
Key information
-18.4%
Earnings growth rate
33.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 97.1% |
| Return on equity | -30.6% |
| Net Margin | -1,393.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Sagimet Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -28 | 13 | 20 |
| 30 Sep 23 | 2 | -27 | 11 | 20 |
| 30 Jun 23 | 0 | -28 | 7 | 22 |
| 31 Mar 23 | 0 | -28 | 6 | 24 |
| 31 Dec 22 | 0 | -30 | 6 | 25 |
| 31 Dec 21 | 0 | -24 | 4 | 19 |
| 31 Dec 20 | 0 | -11 | 3 | 8 |
Quality Earnings: SGMT is currently unprofitable.
Growing Profit Margin: SGMT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SGMT is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.
Accelerating Growth: Unable to compare SGMT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SGMT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: SGMT has a negative Return on Equity (-30.61%), as it is currently unprofitable.